Abstract：
The rising costs of cancer care with the introduction of new agents are a challenge. The impact of these costs differs among countries. We compare costs for metastatic prostate cancer, with prices normalized to international dollars, as an example that highlights the need for cost-effectiveness analyses in trials and treatment guidelines.
摘要：
随着新药物的引入，癌症护理成本的上升是一个挑战。这些成本的影响因国家而异。我们比较转移性前列腺癌的费用，随着价格对国际美元的正常化，作为一个例子，突出了在试验和治疗指南中进行成本效益分析的必要性。
